Biohaven Ltd. (BHVN) Cash Flow Statement

The OCF/NI ratio has ranged from 0.52 to 1.15, indicating that cash burn is often deeper than reported net losses. This suggests that non-cash charges like SBC and D&A are not fully offsetting working capital swings, and the company's cash consumption is a more reliable gauge of its funding needs than net income.

The FCF trajectory shows a slight narrowing in the latest quarter, but this is likely due to timing of working capital changes rather than a fundamental improvement. With no revenue, FCF is entirely driven by R&D spending, which remains elevated as pivotal trials for BHV-7000 and MoDE programs advance. Investors should monitor whether the burn rate stabilizes or escalates as enrollment expands.

The near-zero CapEx underscores a virtual biotech model with outsourced manufacturing and no significant fixed assets. This implies that the company's cash burn is almost entirely operational, primarily funding clinical trials and personnel. The lack of capital intensity means that future scalability will depend on partnerships or licensing rather than internal manufacturing capacity.

The volatility in working capital suggests timing differences in payments to CROs and other vendors, which can temporarily mask or amplify the underlying cash burn. The positive swing in 2026Q2 may indicate delayed payments or prepayments, but without revenue, these swings are not indicative of operational efficiency. Analysts should adjust for these swings to assess the true run-rate burn.

The absence of capital returns is typical for a clinical-stage biotech, but it highlights that every dollar raised is funneled into R&D. Given the high burn rate and negative equity, the company will likely need to raise additional capital through equity offerings, which could dilute existing shareholders. Management's history of selling the CGRP franchise suggests a willingness to divest assets, but current deployment is purely investment-oriented.

The gap between net income and operating cash flow is largely due to non-cash charges like stock-based compensation and depreciation, which totaled over $200M in the period. This divergence suggests that reported losses overstate the immediate cash drain, but the underlying burn remains substantial. The cumulative cash consumption of $1.43B underscores the need for continuous external funding, and the company's ability to secure financing at favorable terms is critical.